Literature DB >> 8799425

Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.

H Takamori1, T Hiraoka, T Yamamoto.   

Abstract

BACKGROUND/AIMS: This study was designed to detect an useful indicator to prognose postoperative hepatic metastases of pancreatic cancer.
MATERIALS AND METHODS: We analyzed clinical and histological data in thirty patients.
RESULTS: Of the ten items analyzed, only preoperative serum CA 19-9 level was indicative of postoperative hepatic metastases. When the patients were classified into two groups in regard to the CA 19-9 level making a boundary at 50 U/ml, the group of CA 19-9 level equal to, or over, 50 U/ml possessed a significantly higher frequency of the hepatic metastases. With a design based on these clinical results, we experimentally studied a correlation between expression of three carbohydrate antigens (CA 19-9, DUPAN-2 and Span-1) and incidence of blood-borne hepatic metastases in nude mice by using six human pancreatic, cancer cell lines. These antigens were immunocytochemically detectable in four cell lines (SUIT-2, AsPC-1, HPAF and Capan-2) and were undetectable in two cell lines (MIA PaCa-2 and BxPC-3). All of the former cell lines formed metastatic lesions in the liver. In contrast, the latter two did not cause hepatic metastases at all. Moreover, these antigens were expressed more intensely in the metastatic foci than in the primary transplanted tumor lesion in the spleen.
CONCLUSION: There is a positive correlation between expression of the carbohydrate antigens and metastatic potential of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799425

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  An autopsy study to clarify characteristics of local recurrence after extended pancreatectomy with intraoperative radiation therapy in patients with pancreatic cancer.

Authors:  Hiroshi Tanaka; Hiroshi Takamori; Keiichiro Kanemitsu; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Langenbecks Arch Surg       Date:  2012-03-01       Impact factor: 3.445

2.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Ritsuko Sawada; Wolfgang W Scholz; Jason S Lewis
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

3.  Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP.

Authors:  Honoré Ngora; Uwe M Galli; Kaoru Miyazaki; Margot Zöller
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

4.  Identification of prognostic factors associated with early mortality after surgical resection for pancreatic cancer--under-analysis of cumulative survival curve.

Authors:  Hiroshi Takamori; Takehisa Hiraoka; Keiichiro Kanemitsu; Tatsuya Tsuji; Chikuma Hamada; Hideo Baba
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

5.  The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells.

Authors:  Esther A Guzmán; Kelly Maers; Jill Roberts; Hilaire V Kemami-Wangun; Dedra Harmody; Amy E Wright
Journal:  Invest New Drugs       Date:  2014-11-23       Impact factor: 3.850

6.  Butyrate inhibits pancreatic cancer invasion.

Authors:  Buckminster Farrow; Piotr Rychahou; Kathleen L O'Connor; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

7.  Onset of liver metastasis after histologically curative resection of pancreatic cancer.

Authors:  Katsuhiko Inoue; Takehisa Hiraoka; Keiichiro Kanemitsu; Hiroshi Takamori; Tatsuya Tsuji; Michio Kawasuji
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

8.  Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with 89Zr-5B1.

Authors:  Jacob L Houghton; Dalya Abdel-Atti; Wolfgang W Scholz; Jason S Lewis
Journal:  Mol Pharm       Date:  2017-02-21       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.